Analysts - Wedbush Securities (original) (raw)
Yun Zhong, PhD
Senior Vice President, Equity Research
ANALYST BIOGRAPHY
Yun Zhong, PhD, is a senior research analyst specializing in biotechnology. Before joining Wedbush, he served as a vice president on the biotech team at Jefferies and held senior biotech analyst roles at Janney Montgomery Scott, Berenberg Capital Markets, and BTIG. Yun's expertise spans orphan diseases, genetic medicine, hematology, neuromuscular diseases, and metabolic disorders. His career began at Cowen and Company, followed by a position at SunTrust Robinson Humphrey.
Yun earned his PhD in neuroscience and molecular biology from Rockefeller University and holds both an MS and a BS in biophysical engineering from Osaka University in Japan. His strong technical background and genuine interest in the scientific aspects of biotechnology allow him to understand therapeutic mechanisms at a molecular level, providing a more objective and differentiated perspective. Yun is particularly focused on gene therapy and genetic medicine, areas where he remains optimistic about its potential to offer significant advancements in patient care.
ANALYST EDGE
Yun’s Edge: His technical expertise and deep understanding of biotech mechanisms set him apart. Yun's ability to objectively analyze data and his comprehensive knowledge of gene therapy and genetic medicine provide a competitive advantage, making him a valuable asset in the biotechnology sector.
COMPANIES UNDER COVERAGE
- Ascendis Pharma (ASND)
- BioMarin Pharmaceuticals (BMRN)
- Keros Therapeutics, Inc. (KROS)
- MoonLake Immunotherapeutics (MLTX)
- Passage Bio (PASG)
- Protagonist Therapeutics (PTGX)
- Rezolute, Inc. (RZLT)
- Rocket Pharmaceuticals (RCKT)
- Voyager Therapeutics (VYGR)